Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric atypical antipsychotic exposure study on growth, sexual maturation, and prolactin-related adverse events
NL-OMON34837Phase 4Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of risperidone in schizophrenia, bipolar disorder (BD), Autism Spectrum Disorder (ASD) and 2 more (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Effects on child growth, Effects on sexual maturation and 1 more. Started Sep 2010; status: active, not recruiting.
02
Drugs
risperidone
03
Conditions
schizophreniabipolar disorder (BD)Autism Spectrum Disorder (ASD)conduct disorder (CD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NL-OMON34837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34837.